Veda Group Ltd reports: Is the stock a buy?

Data analytics business Veda Group Ltd (ASX:VED) is on track to achieve full-year profit guidance.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Veda Group Ltd (ASX: VED) has reported a half-year net profit after tax (NPAT) of $38.06 million which compares favourably to the $12.48 million loss it recorded in the same period last year. The result was underpinned by strong sales growth whereby revenues for the period jumped 11% to $163 million.

So What: The data analytics business said that revenue growth was driven by all business lines, while expansion in its B2C and Marketing business line played a particularly strong role, with revenues up 29.9% against the prior corresponding period. Consumer Risk and Identity revenues were up 8.7%, while Commercial Risk and Information Services revenues jumped 7.5%.

However, these gains were offset somewhat by higher operating costs which grew 11.5% on a pro-forma basis to $93.7 million. This came as a result of expenses related to delivering sales growth, while heavy investments in staff were also made to support the transition into Comprehensive Credit Reporting. As such, pro-forma EBITDA (earnings before interest, tax, depreciation and amortisation) was up 10.4% to $62.8 million.

Veda Group also announced that its Chief Data Officer, Simon Bligh, has resigned from his role citing family reasons. The company is close to appointing someone to replace him with details of the appointment to be made in the near future.

Now What: Veda Group's CEO, Nerida Caesar, confirmed the company's full-year guidance to advise for "at least low double digit growth over FY14" for EBITDA, while its NPAT growth rate will be slightly higher than the EBITDA growth rate. Although the stock isn't cheap at today's price of $2.35, it still appears to be an excellent buy for long-term focused investors.

Motley Fool contributor Ryan Newman owns shares in Veda Group Ltd. You can follow Ryan on Twitter @ASXvalueinvest.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »